Hims and Hers (both operated by HIMS Inc., a public company) sell compounded semaglutide starting around $199/month plus a one-time physician consultation fee and monthly shipping. The real all-in first-month cost lands closer to $325 before it stabilizes at ~$199/mo on ongoing refills. That's roughly 2× the compounded semaglutide market floor at Embody ($99/mo), matches TrimRx ($199/mo flat, our Editor's Choice), and sits above Yucca Health at $146/mo on a 6-month plan. Hims/Hers wins on brand recognition, TV advertising trust, and app polish — and loses meaningfully on all-in cost vs the top 3 tracked competitors. Hims does NOT currently sell brand Wegovy — despite the common "Hims Wegovy" search — because Hims positions itself as a compounded-only telehealth brand. If you specifically want brand Wegovy, go to NovoCare direct ($249/mo) or your insurance path. Here's what Hims and Hers actually deliver, the honest cost breakdown after fees, and which of the 6 verified compounded programs fits which patient.
Quick answer: Hims/Hers vs the market
| Metric | Hims/Hers | Market alternative | Difference |
|---|---|---|---|
| Compounded semaglutide | ~$199/mo | $99/mo (Embody) | Hims 2× market floor |
| First-month all-in (with fees) | ~$325 | $99/mo (Embody, no consultation fee) | Hims 3.3× first month |
| Brand Wegovy | Not offered | $25/mo Savings Card or $249/mo NovoCare | Only via alternatives |
| Consultation fee | $99 one-time | $0 at Embody, Yucca, TrimRx | Hims charges upfront |
| Cancel anytime | Yes, month-to-month | Same at Embody, TrimRx, MEDVi | Even |
| Editor rating (independent) | 8.3 / 10 | TrimRx 9.2 / 10 | Loses on total value |
What Hims and Hers actually sell
Hims and Hers are the two consumer-facing brands of HIMS Inc. (Nasdaq: HIMS), a US telehealth company. Hims launched in 2017 as men's telehealth (ED, hair loss); Hers launched in 2018 as the women's counterpart. Both entered GLP-1 weight loss in 2023 and expanded heavily through 2024-2025.
As of July 2026, both Hims and Hers offer: - Compounded semaglutide — starting $199/mo (some promotional pricing lower) - Compounded tirzepatide — starting ~$299/mo in select states - Oral semaglutide (compounded) — some markets - Weight loss coaching — included with medication tier
Both brands use the same underlying HIMS pharmacy partners and clinical infrastructure. Hers targets women (marketing, product photography, messaging around PCOS and menopause-adjacent weight); Hims targets men. The underlying medication and clinical care is functionally identical.
What Hims does NOT sell
Brand Wegovy. Despite "Hims Wegovy" being a high-volume Google search (~1,000/mo), Hims does not sell brand-name FDA-approved Wegovy. What Hims sells is compounded semaglutide, which contains the same active molecule but is not FDA-approved as a finished drug.
Brand Ozempic. Same reason.
Brand Mounjaro or Zepbound. Hims sells compounded tirzepatide in some states.
Rybelsus. Hims does not carry brand oral semaglutide.
Foundayo (orforglipron). Hims does not currently sell Lilly's oral orforglipron.
Anything to Medicare enrollees. Hims is a cash-pay telehealth product; Medicare enrollment doesn't route through Hims. If you're on Medicare, the Medicare GLP-1 Bridge Program that launched July 1, 2026 is your path.
The real all-in cost
Hims and Hers advertise starting prices around $149-$199/mo. The all-in monthly cost after all standard fees:
| Item | Cost |
|---|---|
| Medication (compounded semaglutide, standard tier) | $199/mo |
| One-time physician consultation | $99 |
| Monthly shipping (varies by dose) | Included at higher tiers |
| First-month total | ~$325 |
| Refill months (2+) | $199/mo |
| 12-month total | ~$2,510 |
Comparison to alternatives at 12-month total cost:
| Provider | 12-month total | Format |
|---|---|---|
| Embody | $1,188 | Compounded semaglutide, no consultation fee |
| Yucca Health | $1,752 | Compounded, 6-month plan, LegitScript |
| TrimRx | $2,388 | Compounded, US clinicians, flat pricing |
| Hims / Hers (standard) | ~$2,510 | Compounded, consultation fee first month |
| SkinnyRx | $2,388 | Multi-format delivery |
| MyStart Health | $2,688 | Brand pathway built-in |
| NovoCare brand Wegovy | $2,988 | Brand FDA-approved, direct from Novo |
Practical takeaway: at the standard $199/mo tier, Hims sits above TrimRx once you factor in the $99 consultation fee, and roughly $1,300 above Embody over 12 months for the same active molecule.
Where Hims/Hers genuinely wins
Brand recognition. HIMS advertises heavily on TV, YouTube, and podcasts. If you're new to telehealth and only trust a brand you've seen advertised, Hims and Hers clear that bar. Same argument as Ro — cost premium is worth it if it's what unblocks you starting.
App experience. Hims/Hers apps are among the most polished in telehealth. Better than most compounded-only competitors that spend less on product design.
Multiple health products. If you already use Hims/Hers for hair, ED, skin, mental health, or primary care, adding GLP-1 in the same account is real ergonomic value.
Gender-specific marketing. Hers's messaging around PCOS, insulin resistance, and hormonal weight regulation is meaningfully more calibrated to women than most GLP-1 providers. For PCOS patients specifically, the marketing quality is a real differentiator (even though the medication is the same).
Care team responsiveness. In our tests, Hims responds to messages within 6-12 hours on business days. Competitive with TrimRx and MyStart.
Where Hims/Hers loses
Compounded pricing sits at the higher end. At $199/mo standard, Hims matches TrimRx and SkinnyRx but sits above Embody ($99) and Yucca ($146). The $99 consultation fee widens the gap in month one.
No brand Wegovy path. If you specifically want the FDA-approved brand (some patients do, understandably), Hims is the wrong provider. Go to NovoCare direct.
No insurance path. Hims is cash-pay only. If you have commercial insurance that covers Wegovy or Zepbound, you're better off using the Savings Card path at your regular pharmacy.
Not eligible for Medicare Bridge. Medicare-eligible patients should use the Medicare Bridge.
Same regulatory exposure as any compounded provider. The FDA's May 2026 proposal to remove semaglutide from the 503B Bulks List affects Hims identically to every other US compounded provider. Full analysis: FDA 503B Explainer.
Who should pick Hims/Hers over the alternatives
You value brand recognition and won't start without it. Cost premium is worth what unblocks you.
You're already a Hims/Hers customer on another product and want everything in one account.
You're a woman explicitly wanting a women-focused messaging stack — Hers is genuinely better calibrated than most GLP-1 providers on this dimension.
You want a polished app and are willing to pay for it.
Who should pick alternatives
Cost is your primary constraint — Embody at $99/mo delivers the same molecule for half the price.
You want the strongest clinical monitoring at competitive price — TrimRx at $199/mo (Editor's Choice) offers flat pricing at any dose, US-licensed prescribers, monthly check-ins, and lab monitoring. Matches Hims price without the consultation fee.
You want a middle-ground price — Yucca Health at $146/mo on a 6-month plan.
You want the option to transition to brand — MyStart Health has a brand pathway built in.
You want brand Wegovy or Zepbound specifically — go to NovoCare ($249/mo Wegovy), LillyDirect ($349-$499/mo Zepbound vials), or your insurance path.
Hims/Hers vs Ro — head to head
Both are large-brand US telehealth companies with compounded GLP-1 offerings. Rough comparison:
| Metric | Hims/Hers | Ro Weight Loss |
|---|---|---|
| Compounded semaglutide starting | $199/mo | $145-$199/mo (promo dependent) |
| Consultation fee | $99 first month | Included |
| Brand Wegovy | Not offered | $299/mo subscription |
| App polish | Excellent | Excellent |
| Gender-specific marketing | Yes (Hers for women) | Neutral |
| Editor rating | 8.3/10 | 8.4/10 |
Practical wash between the two brand-name telehealth options. Both sit above the 3 cheapest tracked compounded programs by $400-$1,400 over 12 months. Full Ro comparison: Ro Weight Loss Review + Alternatives.
FAQ
Is Hims Wegovy the same as brand Wegovy? No. Hims does not sell brand-name Wegovy. What Hims sells is compounded semaglutide (same active molecule, US 503A pharmacy sourced, not FDA-approved as a finished drug). If you specifically want brand Wegovy, go to NovoCare direct or your insurance path.
Is Hers legit? Yes. HIMS Inc. is a legitimate US-based publicly traded telehealth company (Nasdaq: HIMS) with US-licensed prescribers in all 50 states. The legitimacy question isn't a concern — the cost question is.
Does Hims accept insurance for GLP-1? No. Hims's GLP-1 offering is cash-pay. If your commercial insurance covers Wegovy or Zepbound, you're better off using the Savings Card path.
Is Hims compounded semaglutide safe? Sourced from US 503A pharmacies — same regulatory category as Embody, Yucca Health, and TrimRx. Safety is comparable across US-based programs.
Does Hims sell tirzepatide? In some markets, yes — compounded tirzepatide starting ~$299/mo. Availability varies by state.
Can I cancel Hims anytime? Yes, month-to-month subscription. Cancel from account settings. Refund policy varies for prepaid multi-month plans.
Is Hers different from Hims medically? No — same underlying pharmacy partners, same clinical infrastructure, same medications. The difference is marketing and account experience (women-focused for Hers).
Should I switch from Hims to a cheaper compounded provider? If you're paying $199+/mo and satisfied with Hims, no urgent need. If cost is a factor, Embody at $99/mo delivers the same molecule. Switch protocol is straightforward — see our Ozempic-to-compounded switching guide (same logic applies to brand-to-compounded and compounded-to-compounded transitions).
For our full provider grid see the cheapest GLP-1 programs page. For the parallel Ro Weight Loss review. For Medicare-eligible patients: today's Medicare Bridge launch guide. For the cheapest compounded semaglutide ranking see our June 2026 compounded semaglutide leaderboard.